Key takeaways
Pharmacogenomics studies how genetic differences affect responses to medicines. For some drugs, a genetic result can help a clinician choose an option or dose. It does not provide a universal list of medicines that will definitely work or never cause side effects.
Why the same medicine can act differently
Proteins help the body absorb, transport, activate and break down medicines. Genetic variants can change how some of those proteins work. Other variants can influence the chance of particular immune reactions. These relationships are specific to the gene and the medicine.
The same biological difference can have different consequences for different drugs. Slower processing might increase exposure to one medicine, while reduced activation could make another less effective. A report therefore needs drug-specific interpretation rather than a general label such as “slow metabolizer” applied to everything.
One gene–medicine example: CYP2C19 and clopidogrel
Clopidogrel is a medicine that needs conversion to an active form. CYP2C19 contributes to that conversion. The CPIC 2022 guideline shows why a genetic result must be translated in stages.
| Layer | What the example says | What it does not say |
|---|---|---|
| Genotype | CYP2C19 *2/*2: two no-function alleles | A prediction about every medicine |
| Predicted phenotype | CYP2C19 poor metabolizer | That the person cannot process all drugs |
| Drug-specific implication | Reduced activation of clopidogrel may reduce its antiplatelet effect | A personal guarantee of treatment failure |
| Clinical decision | The prescriber checks the indication, alternatives, other medicines and clinical risks | Permission to stop, replace or change a dose independently |
The same gene result can matter differently for another medicine. A useful report connects the particular gene–drug pair to identified guidance and the actual prescribing question.
Genes are only part of the explanation
Age, organ function, other medicines, the underlying illness and additional factors can also influence response. A useful genetic result is interpreted alongside these details. It does not replace discussion of symptoms, side effects or interactions with a clinician or pharmacist.
Evidence also varies. Some gene–drug relationships support clear prescribing guidance, while others remain under investigation. The presence of an association in a database does not mean that every person should be tested before taking that drug.
Making sense of a report
Ask which variants were examined, how the laboratory translated them into a predicted drug-response category and which current guidance supports any proposed change. A colour-coded commercial report can look definitive even when the evidence or the test’s coverage is limited.
Genetic information may remain useful over time, but its interpretation and prescribing guidance can evolve. Keeping the original report available to the care team is more informative than remembering that a medicine appeared in a red or green column.
Questions for your prescriber or pharmacist
- Is there a well-established gene–drug relationship relevant to this medicine?
- Would testing change an actual prescribing decision?
- What other factors could explain my response?
- How will the result be recorded for future care?
Do not change a prescribed medicine or dose on the basis of an online interpretation alone. The useful role of pharmacogenomics is to support a clinical decision with additional evidence. It cannot guarantee a side-effect-free treatment or replace the follow-up needed to see how a medicine is working in practice.